| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 19th August 2020 | Gerrit Dispersyn | 2,000 | Open or private purchase | $2.50 | $5,000.00 |
| 1st March 2020 | Gerrit Dispersyn | 673 | Payment by withholding | $2.93 | $1,971.89 |
| 18th November 2019 | Caitlin Kontulis | 237,500 | Grant/award etc. | $0.10 | $23,750.00 |
| 18th November 2019 | Robert L Ferrara | 127,500 | Grant/award etc. | $0.10 | $12,750.00 |
| 18th November 2019 | Geert Cauwenbergh | 225,000 | Grant/award etc. | $0.10 | $22,500.00 |
| 18th November 2019 | Gerrit Dispersyn | 350,000 | Grant/award etc. | $0.10 | $35,000.00 |
| 18th November 2019 | Robert J Bitterman | 300,000 | Grant/award etc. | $0.10 | $30,000.00 |
| 1st August 2019 | Gerrit Dispersyn | 1,236 | Payment by withholding | $0.40 | $498.11 |
| 1st August 2019 | Geert Cauwenbergh | 1,751 | Payment by withholding | $0.40 | $705.65 |
| 1st August 2019 | Caitlin Kontulis | 749 | Payment by withholding | $0.40 | $301.85 |
R Xi Pharmaceuticals Corp
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Ticker: RXII
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1533040
Employees:
Exchange: None
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
